Loading...
Efficacy and safety of esmirtazapine in adult outpatients with chronic primary insomnia: a randomized, double-blind placebo-controlled study and open-label extension
STUDY OBJECTIVES: Esmirtazapine (1.5–4.5 mg) has demonstrated short-term sleep-promoting effects in nonelderly outpatients with chronic insomnia. This phase 3, randomized, double-blind study (NCT00631657) and its open-label extension (NCT00750919) investigated efficacy and safety of long-term esmirt...
Na minha lista:
| Udgivet i: | J Clin Sleep Med |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Academy of Sleep Medicine
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7970588/ https://ncbi.nlm.nih.gov/pubmed/32351205 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5664/jcsm.8526 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|